Equities

HUTCHMED (China) Ltd

HCM:LSE

HUTCHMED (China) Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)214.00
  • Today's Change-4.00 / -1.83%
  • Shares traded5.07k
  • 1 Year change-5.52%
  • Beta1.2595
Data delayed at least 20 minutes, as of Feb 06 2026 16:28 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year HUTCHMED (China) Ltd's revenues fell -24.80% from 838.00m to 630.20m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 100.78m to 37.73m, a -62.56% decrease.
Gross margin44.15%
Net profit margin77.64%
Operating margin-3.27%
Return on assets30.79%
Return on equity47.42%
Return on investment40.72%
More ▼

Cash flow in USDView more

In 2024, cash reserves at HUTCHMED (China) Ltd fell by 129.63m. However, the company earned 497.00k from its operations for a Cash Flow Margin of 0.08%. In addition the company used 96.06m on investing activities and also paid 30.67m in financing cash flows.
Cash flow per share4.30
Price/Cash flow per share5.44
Book value per share11.01
Tangible book value per share11.01
More ▼

Balance sheet in USDView more

HUTCHMED (China) Ltd has a Debt to Total Capital ratio of 7.00%, a lower figure than the previous year's 7.52%.
Current ratio4.65
Quick ratio4.51
Total debt/total equity0.076
Total debt/total capital0.070
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.